171 related articles for article (PubMed ID: 22809091)
21. Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures.
Chevrier RL; Assalian A; Duperré J; Lesk MR
Ophthalmic Surg Lasers; 1999 Mar; 30(3):199-204. PubMed ID: 10100253
[TBL] [Abstract][Full Text] [Related]
22. Prophylactic use of timolol maleate to prevent intraocular pressure elevation after Nd-YAG laser posterior capsulotomy.
Cai JP; Cheng JW; Wei RL; Ma XY; Jiang F; Zhu H; Li Y
Int Ophthalmol; 2008 Feb; 28(1):19-22. PubMed ID: 17585375
[TBL] [Abstract][Full Text] [Related]
23. A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension.
Hommer A; Sperl P; Resch H; Popa-Cherecheanu A; Qiao C; Schmetterer L; Garhöfer G
J Ocul Pharmacol Ther; 2012 Dec; 28(6):569-75. PubMed ID: 22775229
[TBL] [Abstract][Full Text] [Related]
24. Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery.
Chen TC
J Cataract Refract Surg; 2005 Sep; 31(9):1707-12. PubMed ID: 16246772
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: a prospective, unmasked study.
Tsai JC; Chang HW
J Ocul Pharmacol Ther; 2005 Dec; 21(6):475-82. PubMed ID: 16386089
[TBL] [Abstract][Full Text] [Related]
26. The prophylactic effect of betaxolol 0.5% versus brimonidine 0.2% on IOP elevation after Nd:YAG laser posterior capsulotomy.
Elmi Sadr N; Saber E; Paknazar F
Clin Exp Optom; 2022 Nov; 105(8):813-816. PubMed ID: 34753412
[TBL] [Abstract][Full Text] [Related]
27. Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab.
Theoulakis PE; Lepidas J; Petropoulos IK; Livieratou A; Brinkmann CK; Katsimpris JM
Klin Monbl Augenheilkd; 2010 Apr; 227(4):280-4. PubMed ID: 20408074
[TBL] [Abstract][Full Text] [Related]
28. The effect of 0.25% apraclonidine in preventing intraocular pressure elevation after Nd:YAG laser posterior capsulotomy.
Simsek S; Ertürk H; Demirok A; Cinal A; Yasar T; Karadenizli C
Eur J Ophthalmol; 1998; 8(3):167-72. PubMed ID: 9793771
[TBL] [Abstract][Full Text] [Related]
29. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
[TBL] [Abstract][Full Text] [Related]
30. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the efficacy and safety of dorzolamide 2% when added to brimonidine 0.2% or timolol maleate 0.5% in patients with primary open-angle glaucoma.
Oztürk F; Ermiş SS; Inan UU; Aşagidag A; Yaman S
J Ocul Pharmacol Ther; 2005 Feb; 21(1):68-74. PubMed ID: 15718830
[TBL] [Abstract][Full Text] [Related]
32. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F
Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832
[TBL] [Abstract][Full Text] [Related]
33. Effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy for glaucoma.
Cho SW; Kim JM; Park KH; Choi CY
Jpn J Ophthalmol; 2010 Sep; 54(5):407-13. PubMed ID: 21052902
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of brimonidine 0.2% in controlling acute postoperative intraocular pressure elevation after phacoemulsification.
Katsimpris JM; Siganos D; Konstas AG; Kozobolis V; Georgiadis N
J Cataract Refract Surg; 2003 Dec; 29(12):2288-94. PubMed ID: 14709288
[TBL] [Abstract][Full Text] [Related]
35. Diurnal intraocular pressure efficacy of the timolol-brimonidine fixed combination and the timolol-dorzolamide fixed combination as a first choice therapy in patients with pseudoexfoliation glaucoma.
Yüksel N; Gök M; Altıntaş O; Cağlar Y
Curr Eye Res; 2011 Sep; 36(9):804-8. PubMed ID: 21851166
[TBL] [Abstract][Full Text] [Related]
36. Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery.
Chen TC; Ang RT; Grosskreutz CL; Pasquale LR; Fan JT
Ophthalmology; 2001 Jun; 108(6):1033-8. PubMed ID: 11382625
[TBL] [Abstract][Full Text] [Related]
37. Effect of a fixed brimonidine-timolol combination on intraocular pressure after phacoemulsification.
Pharmakakis N; Giannopoulos K; Stasinos S; Makri OE; Georgakopoulos CD
J Cataract Refract Surg; 2011 Feb; 37(2):279-83. PubMed ID: 21241910
[TBL] [Abstract][Full Text] [Related]
38. Effect of antiglaucoma agents on postoperative intraocular pressure after cataract surgery with Viscoat.
Borazan M; Karalezli A; Akman A; Akova YA
J Cataract Refract Surg; 2007 Nov; 33(11):1941-5. PubMed ID: 17964402
[TBL] [Abstract][Full Text] [Related]
39. Bleb failure and intraocular pressure rise following Nd: Yag laser capsulotomy.
Diagourtas A; Petrou P; Georgalas I; Oikonomakis K; Giannakouras P; Vergados A; Papaconstantinou D
BMC Ophthalmol; 2017 Feb; 17(1):18. PubMed ID: 28228121
[TBL] [Abstract][Full Text] [Related]
40. [Phase III clinical trial of brimonidine in patients with primary open-angle glaucoma and ocular hypertension--comparison of the effects of brimonidine monotherapy versus timolol monotherapy, or combination brimonidine/prostaglandins therapy versus combination placebo/prostaglandins therapy].
Araie M; Yamazaki Y; Sugiyama K; Kuwayama Y; Tanihara H
Nippon Ganka Gakkai Zasshi; 2012 Oct; 116(10):955-66. PubMed ID: 23285843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
